Cargando…
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area
OBJECTIVE: Regulatory agencies require the assessment of cardiovascular (CV) safety for new type 2 diabetes (T2D) therapies through CV outcome trials (CVOTs). However, patients included in CVOTs assessing sodium-glucose cotransporter-2 inhibitors (SGLT2i) might not be representative of those seen in...
Autores principales: | Canivell, Silvia, Mata-Cases, Manel, Vlacho, Bogdan, Gratacòs, Mònica, Real, Jordi, Mauricio, Dídac, Franch-Nadal, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877986/ https://www.ncbi.nlm.nih.gov/pubmed/31815146 http://dx.doi.org/10.1155/2019/2018374 |
Ejemplares similares
-
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia
por: Franch-Nadal, Josep, et al.
Publicado: (2019) -
Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007–2018
por: Mata-Cases, Manel, et al.
Publicado: (2022) -
Potential Risk of Overtreatment in Patients with Type 2 Diabetes Aged 75 Years or Older: Data from a Population Database in Catalonia, Spain
por: Mata-Cases, Manel, et al.
Publicado: (2022) -
Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007–2013 in Catalonia: a population-based study
por: Mata-Cases, Manel, et al.
Publicado: (2016) -
Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study
por: Vlacho, Bogdan, et al.
Publicado: (2021)